[First experience with the use of granulocyte-macrophage colony stimulating factor in pediatric oncology].
Authors report their first experiences with the application of granulocyte-macrophage colony stimulating factor in 12 pediatric cancer patients (14 cases). The drug was given in a 5 micrograms/kg single daily dose subcutaneously. Patients were divided into three main indication groups: 1. Severe neutropenia (white blood cell count < 1.0 G/l) and sepsis (6 patients); 2. Prolonged neutropenia (white blood cell count: 1.0-2.0 G/l) and delay in treatment (3 patients); 3. Dose-escalation of chemotherapy in therapy-resistant cases (4 patients). Authors report that in all cases a substantial raise in white blood cell count could be achieved after 5-6 days of granulocyte-macrophage colony stimulating factor treatment. No side effects were detected except of a moderate local pain at the site of the injection. Authors suggest that in the above described dose and way of administration granulocyte-macrophage colony stimulating factor can be an effective agent in the treatment of chemotherapy-induced neutropenia in paediatric oncology.
Ferencz
T
T
II. Gyermekgyógyászati Klinika, Semmelweis Orvostudományi Egyetem, Budapest.
Csáki
C
C
Koós
R
R
Schuler
D
D
Borsi
J
J
D000293:Adolescent; D000367:Age Factors; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D007223:Infant; D007279:Injections, Subcutaneous; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D009503:Neutropenia / Q000139:chemically induced / Q000628:therapy*
D000970:Antineoplastic Agents; D016178:Granulocyte-Macrophage Colony-Stimulating Factor
Elsö tapasztalataink a granulocita-makrofág kolóniastimuláló faktor alkalmazásáról a gyermekgyógyászati onkológiában.